Sana Biotechnology Statistics
Share Statistics
Sana Biotechnology has 223.27M shares outstanding. The number of shares has increased by 12.85% in one year.
| Shares Outstanding | 223.27M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.43% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 122.43M |
| Failed to Deliver (FTD) Shares | 10.00K |
| FTD / Avg. Volume | 0.65% |
Short Selling Information
The latest short interest is 34.28M, so 15.36% of the outstanding shares have been sold short.
| Short Interest | 34.28M |
| Short % of Shares Out | 15.36% |
| Short % of Float | 28.09% |
| Short Ratio (days to cover) | 32.61 |
Valuation Ratios
The PE ratio is -2.8 and the forward PE ratio is -2.98.
| PE Ratio | -2.8 |
| Forward PE | -2.98 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 2.76 |
| P/FCF Ratio | -2.9 |
| PEG Ratio | n/a |
Enterprise Valuation
Sana Biotechnology Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 3.31, with a Debt / Equity ratio of 0.
| Current Ratio | 3.31 |
| Quick Ratio | 3.31 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.99% and return on capital (ROIC) is -83.48%.
| Return on Equity (ROE) | -0.99% |
| Return on Assets (ROA) | -0.5% |
| Return on Capital (ROIC) | -83.48% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -863.58K |
| Employee Count | 328 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -52.87% in the last 52 weeks. The beta is 1.44, so Sana Biotechnology 's price volatility has been higher than the market average.
| Beta | 1.44 |
| 52-Week Price Change | -52.87% |
| 50-Day Moving Average | 3.23 |
| 200-Day Moving Average | 6.04 |
| Relative Strength Index (RSI) | 34.03 |
| Average Volume (20 Days) | 1.53M |
Income Statement
In the last 12 months, Sana Biotechnology had revenue of $0 and earned -$283.25M in profits. Earnings per share was $-1.46.
| Revenue | 0 |
| Gross Profit | -30.86M |
| Operating Income | -326.90M |
| Net Income | -283.25M |
| EBITDA | -252.39M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.46 |
Balance Sheet
The company has $133.52M in cash and $104.10M in debt, giving a net cash position of $29.42M.
| Cash & Cash Equivalents | 133.52M |
| Total Debt | 104.10M |
| Net Cash | 29.42M |
| Retained Earnings | -1.34B |
| Total Assets | 559.39M |
| Working Capital | 163.15M |
Cash Flow
In the last 12 months, operating cash flow was -$253.58M and capital expenditures -$20.03M, giving a free cash flow of -$273.61M.
| Operating Cash Flow | -253.58M |
| Capital Expenditures | -20.03M |
| Free Cash Flow | -273.61M |
| FCF Per Share | -1.41 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
SANA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -77.25% |
| FCF Yield | -65.01% |
Analyst Forecast
The average price target for SANA is $11.5, which is 508.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $11.5 |
| Price Target Difference | 508.5% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -4.33 |
| Piotroski F-Score | 3 |